Mechanisms of the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes (T2D).

Trial Profile

Mechanisms of the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes (T2D).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
    • 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top